Literature DB >> 29224113

Sex, Gender, and Transgender: Metabolic Impact of Cross Hormone Therapy.

Roberta de Souza Santos1, Aaron P Frank1, Michael Douglas Nelson2,3,4,5, Maurice M Garcia6,7,8, Biff F Palmer9, Deborah J Clegg10.   

Abstract

Most preclinical and clinical, animal, and human research has been biased with respect to sex and even more so with respect to gender. In fact, little is known about the impact of sex and even less about the influence of gender on overall metabolic processes. The National Institutes of Health has recognized this gap in scientific knowledge and now mandates that studies be conducted in both sexes and to include gender as variables influencing physiological processes such as metabolism. It is therefore critical to understand and appreciate how to incorporate sex and gender in preclinical and clinical research in order to enhance our understanding of the mechanisms by which metabolic processes differ by sex and gender. In this chapter, we define sex and gender and discuss when sex and gender are not aligned, such as that which occurs in transgender individuals, and how this impacts metabolic processes. We discuss the importance of understanding the influence and interactions between sex hormones and sex chromosomes rather than focusing on their relative contributions to metabolism in isolation. This knowledge will optimize therapies specific for individuals which need to encompass sex and gender.

Entities:  

Mesh:

Year:  2017        PMID: 29224113     DOI: 10.1007/978-3-319-70178-3_27

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Virilizing doses of testosterone decrease circulating insulin levels and differentially regulate insulin signaling in liver and adipose tissue of females.

Authors:  Kadden H Kothmann; Victoria Jacobsen; Emily Laffitte; Corinne Bromfield; Matthew Grizzaffi; Monica Jarboe; Andrea G Braundmeier-Fleming; Janice M Bahr; Romana A Nowak; Annie E Newell-Fugate
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-04-26       Impact factor: 5.900

2.  Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus.

Authors:  Soyeon Kang; Yong-Moon Park; Dong Jin Kwon; Youn-Jee Chung; Jeong Namkung; Kyungdo Han; Seung-Hyun Ko
Journal:  Diabetes Metab J       Date:  2022-01-24       Impact factor: 5.893

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.